Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × pasireotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pituitary Neoplasms 3 Nelson Syndrome 2 Multiple Myeloma 2 Carcinoid Tumor 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Small Cell Lung Carcinoma 1 Serotonin Syndrome 1 Sarcoma, Synovial 1 Prostatic Neoplasms 1 Prolactin-Producing Pituitary Tumor 1 Primary Inoperable Thymoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pituitary ACTH Hypersecretion 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Meningioma 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulinoma 1 Hyperinsulinism 1 Hematologic Neoplasms 1 Growth Disorders 1 Gigantism 1

Interventions

Everolimus 9 Cisplatin 7 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Nivolumab 4 Etoposide 4 Carboplatin 4 Capecitabine 4 Irinotecan 3 sintilimab 2 pembrolizumab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01563354 2021-04-02

LUNA

Novartis

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡